Clinical analysis and follow up study of chronic granulomatous disease with neonatal onset
-
By
-
Dongwei Zhang
-
Xuehua Xu
-
Huifeng Fan
-
Gan Zhou
-
Wenyan Li
-
Diyuan Yang
-
Peiqiong Wu
-
Gen Lu
-
July 9, 2026
-
Clinical Scorecard: Clinical Evaluation and Longitudinal Study of Neonatal-Onset Chronic Granulomatous Disease
At a Glance
| Category | Detail |
|---|
| Condition | Chronic Granulomatous Disease (CGD) |
| Key Mechanisms | Defect in phagocytic function of the innate immune system due to mutations in NADPH oxidase enzyme complex genes. |
| Target Population | Neonates diagnosed with CGD |
| Care Setting | Pediatric immunology and infectious disease management |
Key Highlights
- Nine male patients with neonatal-onset CGD were studied.
- Pneumonia was observed in 88.9% of patients, with Aspergillus species in 62.5%.
- All patients had hemizygous variants in the CYBB gene.
- Three patients died during initial hospitalization due to disease progression.
- Hematopoietic stem cell transplantation (HSCT) led to complete clinical remission in two patients.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of CGD includes neutrophil respiratory burst tests and genetic analysis.
Management
- Management may include HSCT for severe cases.
Monitoring & Follow-up
- Follow-up includes monitoring for recurrent infections and growth and developmental status.
Risks
- Patients are at high risk for severe bacterial and fungal infections.
Patient & Prescribing Data
Neonates with CGD presenting with severe infections.
Aspergillus species are common pathogens; HSCT can improve prognosis.
Clinical Best Practices
- Early diagnosis through genetic testing and respiratory burst assays is crucial.
- Close monitoring of infection signs and symptoms is essential.
Related Resources & Content
